Coronavirus / COVID

Although news of the delta variant has been front and center, the lambda variant in South America is another strain that public health officials are watching.

Reviewers attribute less severe COVID-19 symptoms in patients with HIV and low CD4 count to reduced capacity for immune reactions including cytokine storm.

Contagion Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the quick evolution of this variant and how vaccination rates have influenced this COVID-19 strain.

With the FDA nod, Regeneron’s monoclonal antibody Regen-Cov (casirivimab and imdevimab) is authorized for the use of the therapy for post-exposure prophylaxis in certain people exposed to SARS-CoV-2 or who are at high risk of exposure to an infected individual.

As the international world struggles to get first doses, the World Health Organization Director General Tedros Adhanom Ghebreyesus says this should also include high-risk populations.

A report says the timetable is for Labor Day or sooner.

Over the last 4 weeks there has been an 80% increase in the continent and the Delta variant is the large cause according to the World Health Organization (WHO).

A study looked at the efficacy of the Pfizer-BioNTech mRNA COVID-19 vaccine in a high-risk national population within a real-world setting.

Ownership language showed an additional boost in appointment and vaccination rates.

Fever was found to not be an early feature of disease.

An early warning system could help significantly help health systems and public officials to prepare.

More and more evidence is pointing towards persistent neuropsychiatric symptoms in people who had the disease.

The study found that ¾ of the cases occurred in fully vaccinated individuals.

Reasons given for not vaccinating were safety issues and low risk for infection.

A conversation with Anna Legreid Dopp, Pharm. D.

With new mask guidance comes questions and confusion, especially with the new strain of COVID-19 and those who have been vaccinated.

Last influenza season was notably quiet during peaking COVID-19 cases. Experts explain what may influence risk of dueling epidemics this year.

With its latest earnings report showing the financial impact of the vaccine, the Delta variant becoming the dominant strain in the US, and concerns of waning immunity, the company believes there is evidence for an additional booster shot.

A new report based on wearable technology finds it takes an average of 79 days for patients’ resting heart rates to return to normal following COVID-19 infection.

Commonly reported issues included delirium, encephalopathies and psychiatric complications.

Public information campaigns may potentially boost rates of vaccination.

As much as 2% of vaccine recipients have reported anaphylaxis following their first shot.

Asymptomatic and symptomatic COVID-19 cases among health care personnel were reduced after vaccination despite surge in infected patients.

The agency is expected to make a statement later today on masking recommendations.

The nasal mucosa was seen to be an essential determinant of overall disease trajectory.

The framework could help officials assess the true burden of disease in certain areas.

Use of remdesivir for COVID-19 was associated with longer hospital stays but was not associated with improved mortality, a recent study of 2344 patients at 123 VA hospitals found.

Modeling showed 1 in 4 infected people pass the infection to a family member.

Pfizer and Moderna will include children aged 5-11 years old in ongoing trials to speak toward risk of rare adverse events observed in other young recipients.

The statement includes over 50 societies and organizations, representing millions of workers.